We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Get ready for the ultimate showdown in the final round of KOL KNOCKOUT™: Oculoplastics Edition! Our winners from Rounds 1 and 2, Andrew G. Lee, MD, and Nicholas Robert Mahoney, MD, return to face off against their final contender, Wendy W. Lee, MD.
Program Chair Andrew R. Harrison, MD, moderates this thrilling thyroid eye disease symposium packed with expert insights, fierce debate, can't-miss clinical pearls, and lots of laughs!
This activity is supported by an unrestricted educational grant from Amgen.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Andrew R. Harrison, MD
Professor of Ophthalmology
and Otolaryngology
Director, Oculofacial Plastic
and Orbital Surgery
Vice Chair, Surgical Services and Quality
Co-director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, MN
Andrew G. Lee, MD
Herb and Jean Lyman Centennial Chair of Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX
Wendy W. Lee, MD
Professor of Clinical Ophthalmology & Dermatology
Oculofacial Plastic & Reconstructive Surgery
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL
Nicholas Robert Mahoney, MD
Chief, Oculoplastics Division
The Johns Hopkins Hospital
Associate Professor of Ophthalmology
Johns Hopkins Wilmer Eye Institute
Baltimore, MD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Andrew R. Harrison, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Horizon Therapeutics, Lassen Therapeutics, RVL, and Viridian Therapeutics. Grant/Research Support: Viridian Therapeutics. Speaker's Bureau: Amgen, Horizon Therapeutics, and RVL.
Andrew G. Lee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alexion, Amgen, AstraZeneca, Bristol Myers Squibb, Horizon Therapeutics, Stoke Therapeutics, Tshaka Bio, and Viridian Therapeutics. Speaker's Bureau: Alexion, Amgen, AstraZeneca, Bristol Myers Squibb, Horizon Therapeutics, Stoke Therapeutics, Tshaka Bio, and Viridian Therapeutics.
Wendy W. Lee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Evolus, Galderma, Horizon, Novabay, Revance, RVL, RoC, Tarsus Pharmacuticals, and Viatris. Grant/Research Support: Viridian.
Nicholas Robert Mahoney, MD, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Get ready for the ultimate showdown in the final round of KOL KNOCKOUT™: Oculoplastics Edition! Our winners from Rounds 1 and 2, Andrew G. Lee, MD, and Nicholas Robert Mahoney, MD, return to face off against their final contender, Wendy W. Lee, MD.
Program Chair Andrew R. Harrison, MD, moderates this thrilling thyroid eye disease symposium packed with expert insights, fierce debate, can't-miss clinical pearls, and lots of laughs!
This activity is supported by an unrestricted educational grant from Amgen.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Andrew R. Harrison, MD
Professor of Ophthalmology
and Otolaryngology
Director, Oculofacial Plastic
and Orbital Surgery
Vice Chair, Surgical Services and Quality
Co-director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, MN
Andrew G. Lee, MD
Herb and Jean Lyman Centennial Chair of Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX
Wendy W. Lee, MD
Professor of Clinical Ophthalmology & Dermatology
Oculofacial Plastic & Reconstructive Surgery
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, FL
Nicholas Robert Mahoney, MD
Chief, Oculoplastics Division
The Johns Hopkins Hospital
Associate Professor of Ophthalmology
Johns Hopkins Wilmer Eye Institute
Baltimore, MD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Andrew R. Harrison, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Horizon Therapeutics, Lassen Therapeutics, RVL, and Viridian Therapeutics. Grant/Research Support: Viridian Therapeutics. Speaker's Bureau: Amgen, Horizon Therapeutics, and RVL.
Andrew G. Lee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alexion, Amgen, AstraZeneca, Bristol Myers Squibb, Horizon Therapeutics, Stoke Therapeutics, Tshaka Bio, and Viridian Therapeutics. Speaker's Bureau: Alexion, Amgen, AstraZeneca, Bristol Myers Squibb, Horizon Therapeutics, Stoke Therapeutics, Tshaka Bio, and Viridian Therapeutics.
Wendy W. Lee, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Evolus, Galderma, Horizon, Novabay, Revance, RVL, RoC, Tarsus Pharmacuticals, and Viatris. Grant/Research Support: Viridian.
Nicholas Robert Mahoney, MD, has had no financial relationships or affiliations with ineligible companies.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Amgen.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Stay current with the best on medical education
